Evidence map›Paper›PMID 41798723›Full record

ArticleJBMR plus2026

Marked regression of calcinosis with canakinumab in hyperphosphatemic familial tumoral calcinosis.

Astrid Dauchez, Julia Herrou, Fadila Mihoubi-Bouvier, Pierre Quartier, Geneviève Baujat, Eugénie Koumakis, Karine Briot, Christian Roux

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JBMR plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Astrid DauchezDepartment of Rheumatology, APHP Centre, Cochin Hospital, 75014 Paris, France.
Julia HerrouDepartment of Rheumatology, APHP Centre, Cochin Hospital, 75014 Paris, France.ORCID https://orcid.org/0000-0002-7618-9503
Fadila Mihoubi-BouvierDepartment of Musculoskeletal Radiology, Cochin Hospital, 75014 Paris, France.
Pierre QuartierPediatric Immuno-Hematology and Rheumatology Unit, RAISE Reference Center (ERN RECONNECT), Necker-Enfants Malades Hospital, 75015 Paris, France.ORCID https://orcid.org/0000-0002-1769-549X
Geneviève BaujatReference Center for Skeletal Dysplasia, INSERM UMR1163, Imagine Institute, Necker-Enfants Malades Hospital, Paris Cité University, 75015 Paris, France.
Eugénie KoumakisDepartment of Rheumatology, APHP Centre, Cochin Hospital, 75014 Paris, France.
Karine BriotDepartment of Rheumatology, APHP Centre, Cochin Hospital, 75014 Paris, France.ORCID https://orcid.org/0000-0002-6238-2601
Christian RouxDepartment of Rheumatology, APHP Centre, Cochin Hospital, 75014 Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyperphosphatemic familial tumoral calcinosis (HFTC) is a rare autosomal recessive disease caused by pathogenic variants in genes involved in phosphate homeostasis, and characterized by elevated serum phosphate levels and the development of ectopic calcifications. Management typically includes phosphate-lowering strategies and, when clinically necessary, surgical debulking of calcifications. Inflammatory flares occur variably and remain poorly understood. We report the case of a 27-yr-old woman with HFTC due to a homozygous

Indexed as

anti-interleukin-1calcinosiscanakinumabhyperphosphatemiainflammatory flare

Identifiers

PMID41798723
PMCPMC12965204

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.